Which has preferable earnings & valuation, DCGO or BDSX?

Biodesix has lower revenue, but higher earnings than DocGo. Biodesix is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DocGo $322.20M 0.13 -$182.40M -$1.96 N/A Biodesix $88.50M 3.40 -$35.26M -$3.17 N/A

Is DCGO or BDSX more profitable?

Biodesix has a net margin of -26.97% compared to DocGo's net margin of -65.29%. DocGo's return on equity of -40.42% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets DocGo -65.29% -40.42% -24.81% Biodesix -26.97% -788.19% -30.33%

Which has higher valuation and earnings, INFU or DCGO?

InfuSystem has higher earnings, but lower revenue than DocGo. DocGo is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InfuSystem $143.34M 1.70 $870K $0.41 29.41 DocGo $322.20M 0.13 -$182.40M -$1.96 N/A

Is INFU or DCGO more profitable?

InfuSystem has a net margin of 1.12% compared to DocGo's net margin of -65.29%. InfuSystem's return on equity of 2.78% beat DocGo's return on equity. Company Net Margins Return on Equity Return on Assets InfuSystem 1.12% 2.78% 1.41% DocGo -65.29% -40.42% -24.81%

Which has higher valuation and earnings, DCGO or LFMD?

LifeMD has lower revenue, but higher earnings than DocGo. LifeMD is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DocGo $322.20M 0.13 -$182.40M -$1.96 N/A LifeMD $194.05M 0.81 $14.35M -$0.05 N/A

Is DCGO or LFMD more profitable?

LifeMD has a net margin of 0.10% compared to DocGo's net margin of -65.29%. DocGo's return on equity of -40.42% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets DocGo -65.29% -40.42% -24.81% LifeMD 0.10% -168.23% -31.27%

Which has stronger valuation and earnings, DCGO or XGN?

Exagen has lower revenue, but higher earnings than DocGo. Exagen is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DocGo $322.20M 0.13 -$182.40M -$1.96 N/A Exagen $66.57M 2.74 -$19.95M -$0.81 N/A

Is DCGO or XGN more profitable?

Exagen has a net margin of -26.61% compared to DocGo's net margin of -65.29%. DocGo's return on equity of -40.42% beat Exagen's return on equity. Company Net Margins Return on Equity Return on Assets DocGo -65.29% -40.42% -24.81% Exagen -26.61% -104.46% -28.93%

Do analysts rate DCGO or JYNT?

DocGo presently has a consensus target price of $2.38, suggesting a potential upside of 472.70%. Given DocGo's stronger consensus rating and higher probable upside, research analysts clearly believe DocGo is more favorable than Joint. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DocGo 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Joint 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has preferable earnings and valuation, DCGO or JYNT?

Joint has lower revenue, but higher earnings than DocGo. DocGo is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DocGo $322.20M 0.13 -$182.40M -$1.96 N/A Joint $54.90M 2.17 $2.91M $0.27 31.15

Is DCGO or JYNT more profitable?

Joint has a net margin of 6.49% compared to DocGo's net margin of -65.29%. Joint's return on equity of 12.02% beat DocGo's return on equity. Company Net Margins Return on Equity Return on Assets DocGo -65.29% -40.42% -24.81% Joint 6.49% 12.02% 3.47%

DocGo (DCGO) Competitors

$0.41 +0.02 (+4.93%)

Closing price 04:00 PM Eastern

Extended Trading

$0.42 +0.00 (+0.55%)

As of 06:49 PM Eastern

Compare

DCGO vs. BDSX, INFU, LFMD, XGN, and JYNT

Should you buy DocGo stock or one of its competitors? DocGo's main competitors and comparable companies include Biodesix (BDSX), InfuSystem (INFU), LifeMD (LFMD), Exagen (XGN), and Joint (JYNT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare services" industry.

How does DocGo compare to Biodesix?

DocGo (NASDAQ:DCGO) and Biodesix (NASDAQ:BDSX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Biodesix has a net margin of -26.97% compared to DocGo's net margin of -65.29%. DocGo's return on equity of -40.42% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-65.29%	-40.42%	-24.81%
Biodesix	-26.97%	-788.19%	-30.33%

In the previous week, Biodesix had 1 more articles in the media than DocGo. MarketBeat recorded 2 mentions for Biodesix and 1 mentions for DocGo. Biodesix's average media sentiment score of 0.69 beat DocGo's score of 0.62 indicating that Biodesix is being referred to more favorably in the news media.

Company	Overall Sentiment
DocGo	Positive
Biodesix	Positive

DocGo has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market. Comparatively, Biodesix has a beta of 0.56, meaning that its stock price is 44% less volatile than the broader market.

Biodesix has lower revenue, but higher earnings than DocGo. Biodesix is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.13	-$182.40M	-$1.96	N/A
Biodesix	$88.50M	3.40	-$35.26M	-$3.17	N/A

56.4% of DocGo shares are owned by institutional investors. Comparatively, 21.0% of Biodesix shares are owned by institutional investors. 5.1% of DocGo shares are owned by insiders. Comparatively, 23.2% of Biodesix shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

DocGo presently has a consensus price target of $2.38, indicating a potential upside of 472.70%. Biodesix has a consensus price target of $31.33, indicating a potential upside of 10.02%. Given DocGo's higher probable upside, research analysts plainly believe DocGo is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Summary

DocGo and Biodesix tied by winning 8 of the 16 factors compared between the two stocks.

How does DocGo compare to InfuSystem?

InfuSystem (NYSE:INFU) and DocGo (NASDAQ:DCGO) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, valuation, dividends and profitability.

In the previous week, InfuSystem had 3 more articles in the media than DocGo. MarketBeat recorded 4 mentions for InfuSystem and 1 mentions for DocGo. InfuSystem's average media sentiment score of 1.75 beat DocGo's score of 0.62 indicating that InfuSystem is being referred to more favorably in the media.

Company	Overall Sentiment
InfuSystem	Very Positive
DocGo	Positive

InfuSystem has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market. Comparatively, DocGo has a beta of 0.99, suggesting that its stock price is 1% less volatile than the broader market.

InfuSystem currently has a consensus price target of $16.67, suggesting a potential upside of 38.20%. DocGo has a consensus price target of $2.38, suggesting a potential upside of 472.70%. Given DocGo's higher possible upside, analysts plainly believe DocGo is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

InfuSystem has higher earnings, but lower revenue than DocGo. DocGo is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InfuSystem	$143.34M	1.70	$870K	$0.41	29.41
DocGo	$322.20M	0.13	-$182.40M	-$1.96	N/A

InfuSystem has a net margin of 1.12% compared to DocGo's net margin of -65.29%. InfuSystem's return on equity of 2.78% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
DocGo	-65.29%	-40.42%	-24.81%

71.1% of InfuSystem shares are held by institutional investors. Comparatively, 56.4% of DocGo shares are held by institutional investors. 10.8% of InfuSystem shares are held by company insiders. Comparatively, 5.1% of DocGo shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

InfuSystem beats DocGo on 13 of the 15 factors compared between the two stocks.

How does DocGo compare to LifeMD?

DocGo (NASDAQ:DCGO) and LifeMD (NASDAQ:LFMD) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.

56.4% of DocGo shares are owned by institutional investors. Comparatively, 35.5% of LifeMD shares are owned by institutional investors. 5.1% of DocGo shares are owned by company insiders. Comparatively, 17.2% of LifeMD shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, LifeMD had 1 more articles in the media than DocGo. MarketBeat recorded 2 mentions for LifeMD and 1 mentions for DocGo. LifeMD's average media sentiment score of 0.94 beat DocGo's score of 0.62 indicating that LifeMD is being referred to more favorably in the news media.

Company	Overall Sentiment
DocGo	Positive
LifeMD	Positive

DocGo currently has a consensus target price of $2.38, indicating a potential upside of 472.70%. LifeMD has a consensus target price of $7.57, indicating a potential upside of 132.25%. Given DocGo's higher possible upside, analysts plainly believe DocGo is more favorable than LifeMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
LifeMD	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70

DocGo has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market. Comparatively, LifeMD has a beta of 2.02, meaning that its share price is 102% more volatile than the broader market.

LifeMD has lower revenue, but higher earnings than DocGo. LifeMD is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.13	-$182.40M	-$1.96	N/A
LifeMD	$194.05M	0.81	$14.35M	-$0.05	N/A

LifeMD has a net margin of 0.10% compared to DocGo's net margin of -65.29%. DocGo's return on equity of -40.42% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-65.29%	-40.42%	-24.81%
LifeMD	0.10%	-168.23%	-31.27%

Summary

LifeMD beats DocGo on 10 of the 16 factors compared between the two stocks.

How does DocGo compare to Exagen?

DocGo (NASDAQ:DCGO) and Exagen (NASDAQ:XGN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

DocGo currently has a consensus price target of $2.38, suggesting a potential upside of 472.70%. Exagen has a consensus price target of $9.63, suggesting a potential upside of 27.99%. Given DocGo's higher possible upside, equities analysts plainly believe DocGo is more favorable than Exagen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Exagen	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

DocGo has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market. Comparatively, Exagen has a beta of 2.05, indicating that its stock price is 105% more volatile than the broader market.

Exagen has lower revenue, but higher earnings than DocGo. Exagen is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.13	-$182.40M	-$1.96	N/A
Exagen	$66.57M	2.74	-$19.95M	-$0.81	N/A

Exagen has a net margin of -26.61% compared to DocGo's net margin of -65.29%. DocGo's return on equity of -40.42% beat Exagen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-65.29%	-40.42%	-24.81%
Exagen	-26.61%	-104.46%	-28.93%

In the previous week, Exagen had 2 more articles in the media than DocGo. MarketBeat recorded 3 mentions for Exagen and 1 mentions for DocGo. Exagen's average media sentiment score of 1.08 beat DocGo's score of 0.62 indicating that Exagen is being referred to more favorably in the news media.

Company	Overall Sentiment
DocGo	Positive
Exagen	Positive

56.4% of DocGo shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 5.1% of DocGo shares are held by insiders. Comparatively, 10.4% of Exagen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Exagen beats DocGo on 12 of the 17 factors compared between the two stocks.

How does DocGo compare to Joint?

DocGo (NASDAQ:DCGO) and Joint (NASDAQ:JYNT) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

DocGo has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market. Comparatively, Joint has a beta of 1.1, meaning that its share price is 10% more volatile than the broader market.

In the previous week, Joint had 1 more articles in the media than DocGo. MarketBeat recorded 2 mentions for Joint and 1 mentions for DocGo. Joint's average media sentiment score of 0.93 beat DocGo's score of 0.62 indicating that Joint is being referred to more favorably in the news media.

Company	Overall Sentiment
DocGo	Positive
Joint	Positive

DocGo presently has a consensus target price of $2.38, suggesting a potential upside of 472.70%. Given DocGo's stronger consensus rating and higher probable upside, research analysts clearly believe DocGo is more favorable than Joint.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Joint	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

56.4% of DocGo shares are held by institutional investors. Comparatively, 76.9% of Joint shares are held by institutional investors. 5.1% of DocGo shares are held by company insiders. Comparatively, 30.2% of Joint shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Joint has a net margin of 6.49% compared to DocGo's net margin of -65.29%. Joint's return on equity of 12.02% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-65.29%	-40.42%	-24.81%
Joint	6.49%	12.02%	3.47%

Joint has lower revenue, but higher earnings than DocGo. DocGo is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.13	-$182.40M	-$1.96	N/A
Joint	$54.90M	2.17	$2.91M	$0.27	31.15

Summary

Joint beats DocGo on 12 of the 16 factors compared between the two stocks.

Get DocGo News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DCGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DCGO vs. The Competition

Export

Metric	DocGo	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$39.10M	$10.05B	$7.31B	$12.78B
Dividend Yield	N/A	2.55%	2.53%	11.03%
P/E Ratio	-0.21	29.48	210.50	22.08
Price / Sales	0.13	5.04	630.29	95.53
Price / Cash	7.14	126.73	79.17	53.57
Price / Book	0.43	4.10	13.01	6.26
Net Income	-$182.40M	$312.92M	$3.46B	$348.07M
7 Day Performance	-3.65%	0.59%	1.95%	1.40%
1 Month Performance	-34.16%	1.13%	8.17%	4.59%
1 Year Performance	-74.40%	16.10%	26.28%	17.05%

DocGo Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DCGO DocGo	3.3741 of 5 stars	$0.41 +4.9%	$2.38 +472.7%	-76.0%	$39.10M	$322.20M	N/A	3,568
BDSX Biodesix	3.4048 of 5 stars	$24.00 +0.9%	$31.33 +30.6%	+229.0%	$253.20M	$88.50M	N/A	220
INFU InfuSystem	4.1793 of 5 stars	$12.27 -1.7%	$16.67 +35.8%	+21.4%	$247.63M	$143.34M	204.53	410	News Coverage Positive News
LFMD LifeMD	3.5255 of 5 stars	$3.45 -0.3%	$7.57 +119.5%	-50.2%	$166.29M	$194.05M	N/A	230
XGN Exagen	3.6466 of 5 stars	$6.66 +1.2%	$9.63 +44.5%	-22.5%	$161.37M	$66.57M	N/A	220

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DCGO) was last updated on 8/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DocGo (DCGO) Competitors